Dr. Alyssa Ann Lebel is a Boston, Massachusetts based psychiatrist who is specialized in Pain Medicine. Active license number of Dr. Alyssa Ann Lebel is 54989 for Pain Medicine in Massachusetts. Her current practice location is 333 Longwood Ave Fl 5, Boston. Patients can reach her at 617-355-7040. Dr. Alyssa Ann Lebel is MD in Pain Medicine and her NPI number (Unique professional ID assigned by NPPES) is 1235123381. Dr. Alyssa Ann Lebel provides a high level of care, either as a primary physician or consultant, for patients experiencing problems with acute, chronic or cancer pain in both hospital and ambulatory settings. Patient care needs may also be coordinated with other specialists.
Complete Profile:
Dr. Alyssa Ann Lebel speciality, credentials, practice address, contact phone number and fax are as below.
Patients can call on the below given phone number for appointment.
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1235123381
NPI Enumeration Date:
06 Sep, 2005
NPI Last Update On:
17 Aug, 2007
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Alyssa Ann Lebel are as mentioned below.
License Number
Specialization
State
Status
54989
Pain Medicine
Massachusetts
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
Dr. Alyssa Ann Lebel 333 Longwood Ave Fl 5, Boston, Massachusetts
Zip:
02115-5711
Phone Number:
617-355-7040
Patients can reach Dr. Alyssa Ann Lebel at 333 Longwood Ave Fl 5, Boston, Massachusetts or can call to book an appointment on 617-355-7040.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.